In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised his …
Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $390, which represents a slight …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $422, following the company’s results, …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target …
In a research report issued Tuesday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a $422 price target, as the company …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN), and raised his price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and slightly raised his price target to $390 (from …
Regeneron Pharmaceuticals (REGN) announced that Eylea has been approved by the European Commission for use in patients with DME. Marketing of Eylea will be initiated …
